Modifications du système pare-excitation maternel en pré- et post-partum et expression somatique du bébé. À partir d’une observation,Elise (1 mois 19 jours)

This article shows how the protective shield system, especially maternal, is at the center of pre- and post-partum sensitive periods. Welcoming a baby is not an easy process. Any parent have to face a lot of psychic tasks that can be increased by their quality of life and events like house or work-moving, isolation from family, difficulties and fears related to pregnancy outcome, etc. The protective shield system, as originally conceived by Freud, already occupies a central place in all subjects but this article shows how it is essential for parents in the pre- and post-partum. Indeed, the psychological work is necessarily so because increased so that to cope with the new situation, the encounter with the baby but also the updating of a number of intrapsychic conflicts. The immaturity of the baby, his dependence and the necessary adjustment for early interactions involved require additional psychological work. The situation of Elise – 1 month 19 days – and her parents proves to us emblematic. We see how the protective shield system, particularly maternal, at prenatal and postpartum period may be weakened, modified and cause, for the baby, a somatic expression rapidly reversible. Sufficient attention to these phases can serve quite appropriate and positive care strategies as in the situation described.     

Flexible modeling of competing risks in survival analysis

Prognostic studies often involve modeling competing risks, where an individual can experience only one of alternative events, and the goal is to estimate hazard functions and covariate effects associated with each event type. Lunn and McNeil proposed data manipulation that permits extending the Cox's proportional hazards model to estimate covariate effects on the hazard of each competing events. However, the hazard functions for competing events are assumed to remain proportional over the entire follow‐up period, implying the same shape of all event‐specific hazards, and covariate effects are restricted to also remain constant over time, even if such assumptions are often questionable. To avoid such limitations, we propose a flexible model to (i) obtain distinct estimates of the baseline hazard functions for each event type, and (ii) allow estimating time‐dependent covariate effects in a parsimonious model. Our flexible competing risks regression model uses smooth cubic regression splines to model the time‐dependent changes in (i) the ratio of event‐specific baseline hazards, and (ii) the covariate effects. In simulations, we evaluate the performance of the proposed estimators and likelihood ratio tests, under different assumptions. We apply the proposed flexible model in a prognostic study of colorectal cancer mortality, with two competing events: ‘death from colorectal cancer’ and ‘death from other causes’. Copyright © 2010 John Wiley & Sons, Ltd.     

Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease

Purpose

Increased type I interferon is considered relevant to the pathology of a number of monogenic and complex disorders spanning pediatric rheumatology, neurology, and dermatology. However, no test exists in routine clinical practice to identify enhanced interferon signaling, thus limiting the ability to diagnose and monitor treatment of these diseases. Here, we set out to investigate the use of an assay measuring the expression of a panel of interferon-stimulated genes (ISGs) in children affected by a range of inflammatory diseases.

Design, Setting, and Participants

A cohort study was conducted between 2011 and 2016 at the University of Manchester, UK, and the Institut Imagine, Paris, France. RNA PAXgene blood samples and clinical data were collected from controls and symptomatic patients with a genetically confirmed or clinically well-defined inflammatory phenotype. The expression of six ISGs was measured by quantitative polymerase chain reaction, and the median fold change was used to calculate an interferon score (IS) for each subject compared to a previously derived panel of 29 controls (where +2 SD of the control data, an IS of >2.466, is considered as abnormal). Results were correlated with genetic and clinical data.

Results

Nine hundred ninety-two samples were analyzed from 630 individuals comprising symptomatic patients across 24 inflammatory genotypes/phenotypes, unaffected heterozygous carriers, and controls. A consistent upregulation of ISG expression was seen in 13 monogenic conditions (455 samples, 265 patients; median IS 10.73, interquartile range (IQR) 5.90–18.41), juvenile systemic lupus erythematosus (78 samples, 55 patients; median IS 10.60, IQR 3.99–17.27), and juvenile dermatomyositis (101 samples, 59 patients; median IS 9.02, IQR 2.51–21.73) compared to controls (78 samples, 65 subjects; median IS 0.688, IQR 0.427–1.196), heterozygous mutation carriers (89 samples, 76 subjects; median IS 0.862, IQR 0.493–1.942), and individuals with non-molecularly defined autoinflammation (89 samples, 69 patients; median IS 1.07, IQR 0.491–3.74).

Conclusions and Relevance

An assessment of six ISGs can be used to define a spectrum of inflammatory diseases related to enhanced type I interferon signaling. If future studies demonstrate that the IS is a reactive biomarker, this measure may prove useful both in the diagnosis and the assessment of treatment efficacy.

     

Cancer incidence and survival among adolescents and young adults in France (1978-1997)

Malignancies are rare young French adults but represent the third significant cause of death in the cohort of 15-24 years of age. The aim of this study was to investigate incidence and survival rates of French adolescents and young adults with cancer. All cases of cancer occuring over a 20-year period (1978-1997) in the cohort of patients aged 15 to 24, were obtained from nine population-based registries (10 % of the French population). Basal cell carcinomas of the skin were excluded. 1161 and 1884 cases were recorded in adolescents and young adults, respectively. Overall incidence rates (IR) were 161.4/10(6) in adolescents aged 15-19 years (M/F ratio = 1.3), and 252.6/10(6) in young adults aged 20-24 years (M/F ratio : 1.2). During the 1978-97 period, the IRs appeared stable over the years, +0.4 % [CI95 % = -2.3 ; +3.1] (p = 0.79) for adolescents and +1.7 % [CI95 % = -4.0 ; +7.3] (p = 0.57) for young adults. Five-year overall survival rates were 69.1 % [CI95 % = 66.4-71.8] for adolescents and 74.5 % [CI95 % = 72.3-76.7] for young adults. The 5-year survival rate for patients 15-24 years improved from 62.0 % (CI95 % = 57.5-66.5) in 1978-82 to 80.2 % (IC95 % = 77.7-82.8) in 1993-97. Noteworthy, results in adolescents and young adults are poor compared to the ones from their younger counterparts, especially in patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and astrocytoma. Further studies are warranted to elucidate whether these differences are due to intrinsic biological properties of the tumor or to differences in clinical practices in the two populations.     

Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM)

We present the main results of the first population-based cancers survival study gathering all French registry data. Survival data on 205,562 cancer cases diagnosed between 01/01/1989 and 31/12/1997 were analysed. Relative survival was estimated using an excess rate model. The evolution of the excess mortality rate over the follow-up period was graphed. The analysis emphasised the effect of age at diagnosis and its variation with time after diagnosis. For breast and prostate cancers, the age-standardised five-year relative survivals were 84% and 77%, respectively. The corresponding results in men and women were 56% versus 58% for colorectal cancer and 12% versus 16% for lung cancer. For some cancer sites, the excess mortality rate decreased to low values by five years after diagnosis. For most cancer sites, age at diagnosis was a negative prognostic factor but this effect was often limited to the first year after diagnosis.